BANGALORE, India, March 13, 2025 /PRNewswire/ — Multi Use Bioreactor Market is Segmented by Type (Manual, Automatic, Semi-Automatic), by Application (Pharmaceuticals, Scientific Research Institution).

According to new survey, Global Multi Use Bioreactor Market is projected to reach USD.

12260 Million in 2029, increasing from USD 6415 Million in 2022, with a CAGR of 9.7% during the period of 2023 to 2029.

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market

Major Factors Driving the Growth of Multi Use Bioreactor Market:

The multi-use bioreactor market is experiencing sustained growth, driven by advancements in biopharmaceutical production, automation, and process optimization. These systems play a vital role in scaling up biologics manufacturing while maintaining cost efficiency and regulatory compliance. Market players are investing in next-generation bioreactor technologies to enhance productivity and meet evolving industry demands.

The integration of artificial intelligence, real-time monitoring, and hybrid bioprocessing solutions is transforming biomanufacturing practices. As personalized medicine and cell-based therapies gain traction, the demand for flexible and high-performance bioreactors is expected to rise. The continuous expansion of global bioprocessing infrastructure reinforces the market’s long-term growth trajectory, positioning multi-use bioreactors as indispensable assets in pharmaceutical and biotechnology sectors.

Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-37Q12337/global-multi-use-bioreactor

TRENDS INFLUENCING THE GROWTH OF THE MULTI USE BIOREACTOR MARKET:

Semi-automatic bioreactors play a crucial role in biopharmaceutical research and industrial fermentation processes by offering a balance between manual control and automation. These systems enable users to adjust key parameters such as temperature, pH, and oxygen levels while leveraging automated controls for consistency. The flexibility of semi-automatic bioreactors makes them ideal for academic institutions, pilot-scale production, and laboratories requiring cost-effective solutions. Their ability to accommodate a wide range of microbial and cell culture processes attracts pharmaceutical companies looking for adaptable production methods. The increasing demand for customized bioproduction, including cell therapy and regenerative medicine, further propels the adoption of semi-automatic bioreactors. These factors drive market growth and expand bioprocessing capabilities globally.

Advertisement

Automatic bioreactors are revolutionizing large-scale biomanufacturing by integrating advanced sensors, AI-driven monitoring, and real-time data analytics. These systems optimize fermentation and cell culture processes, reducing human intervention while ensuring precision and reproducibility. The pharmaceutical industry heavily relies on automatic bioreactors for monoclonal antibody production, vaccine development, and protein synthesis. Their ability to maintain sterile conditions and minimize contamination risks makes them indispensable for biologics manufacturing. The growing trend of continuous bioprocessing and process intensification has further increased demand for automatic bioreactors, enabling high-throughput production. Additionally, biopharma firms are investing in these systems to enhance scalability, reduce operational costs, and streamline regulatory compliance, fueling the expansion of the multi-use bioreactor market.

The pharmaceutical industry is a major driver of the multi-use bioreactor market, as bioreactors are essential for drug discovery, development, and commercial-scale manufacturing. Biopharmaceutical companies use these systems for cell culture applications, vaccine production, and biosimilar development. With the rise of personalized medicine and gene therapy, pharmaceutical firms are shifting toward modular and flexible bioreactor systems to meet evolving production demands. Regulatory agencies emphasize compliance with Good Manufacturing Practices (GMP), encouraging the adoption of high-quality multi-use bioreactors. Additionally, the rapid response to emerging diseases, such as COVID-19, has accelerated investments in bioreactor technology for vaccine research and development. This increasing reliance on bioreactors for pharmaceutical applications significantly contributes to market growth.

The growing prevalence of chronic diseases and the rise of biologics have fueled demand for biopharmaceuticals, driving the need for efficient multi-use bioreactors. As monoclonal antibodies, gene therapies, and biosimilars gain prominence, manufacturers require scalable bioprocessing solutions. Multi-use bioreactors allow efficient production while ensuring consistency and regulatory compliance. Their ability to support various cell lines and microbial cultures enhances flexibility in drug development. This surge in biologics manufacturing directly contributes to market expansion.

Although single-use bioreactors are gaining traction, multi-use bioreactors remain crucial due to their cost efficiency in large-scale production. Many facilities adopt hybrid systems combining single-use and stainless-steel bioreactors to maximize flexibility. Hybrid approaches allow manufacturers to balance cost savings with operational efficiency, reducing turnaround time while maintaining sterility. This transition toward mixed-use systems supports sustainable biomanufacturing and meets evolving industry needs.

The rise of personalized therapies, including CAR-T cell therapies and regenerative medicine, has necessitated adaptable bioprocessing solutions. Multi-use bioreactors support customized production of small-batch biologics tailored to individual patient needs. Their scalability and versatility make them ideal for emerging cell-based therapies. As precision medicine gains momentum, demand for bioreactors catering to specialized manufacturing continues to grow.

While single-use systems dominate small-scale applications, multi-use bioreactors remain cost-effective for high-volume biomanufacturing. Their ability to process large batches of biologics reduces per-unit costs, making them economically viable for commercial production. Established pharmaceutical companies leverage multi-use systems for blockbuster drug manufacturing, ensuring long-term cost savings. This economic advantage reinforces their continued market demand.

Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-37Q12337&lic=single-user

MULTI USE BIOREACTOR MARKET SHARE

North America dominates the market due to the presence of leading biopharma companies, a robust research ecosystem, and significant government funding. Europe follows closely, with stringent regulatory standards and strong biomanufacturing capabilities.

Key Companies:

Advertisement

• Sartorius
• Thermo Fisher Scientific Inc
• General Electric
• Eppendorf
• Merck KGaA
• Pall Corporation
• ZETA
• Pierre Guerin
• Praj Hipurity Systems Limited
• Bioengineering AG
• Infors
• SOLARIS BIOTECHNOLOGY srl
• Bbi-biotech
• PBS Biotech;Inc.
• GEA Group Aktiengesellschaft
• CerCell A/S

Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-37Q12337/Global_Multi_Use_Bioreactor_Market

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!

–          Perfusion Bioreactor market was valued at USD 703.66 Million in 2024 and is anticipated to reach USD 1,153.63 Million by 2031, witnessing a CAGR of 7.19% during the forecast period 2025-2031.
–          Lab Scale Bioreactor market was valued at USD 2369 Million in 2023 and is anticipated to reach USD 4337.5 Million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
–          Single-Use Bioreactors (SUB) Market was valued at USD 220 Million in the year 2024 and is projected to reach a revised size of USD 275 Million by 2031, growing at a CAGR of 3.3% during the forecast period.
–          Bioreactors Market
–          Pharmaceutical Fermentation Bioreactor market is projected to grow from USD 6256 Million in 2024 to USD 11080 Million by 2030, at a Compound Annual Growth Rate (CAGR) of 10.0% during the forecast period.
–          Bioreactors and Fermentors Market
–          Cell Culture Bioreactors Market
–          Bubble Column Bioreactor Market
–          Membrane Bioreactor Systems market was valued at USD 3307.4 Million in 2023 and is anticipated to reach USD 4996.5 Million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
–          Fixed Bed Bioreactors Market
–          Micro Bioreactors Market revenue was USD 133.9 Million in 2022 and is forecast to a readjusted size of USD 246.5 Million by 2029 with a CAGR of 9.0% during the forecast period (2023-2029).

DISCOVER OUR VISION: VISIT ABOUT US!

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.

GET A FREE QUOTE

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335

Advertisement

Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753

https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish
https://www.facebook.com/valuatesjapanese
https://valuatesreportspanish.blogspot.com/
https://valuateskorean.blogspot.com/
https://valuatesgerman.blogspot.com/
https://valuatesreportjapanese.blogspot.com/ 

Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/multi-use-bioreactor-market-in-pharmaceuticals-and-research-institutions-to-hit-usd-12-26-billion-by-2029–growing-9-7-annually–valuates-reports-302401344.html

Company announcement No. 578, 2025

CEO Jörg Brinkmann have purchased shares in H+H International A/S

COPENHAGEN, Denmark, March 13, 2025 /PRNewswire/ — H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them.

1.	Advertisement Details of the person discharging managerial responsibilities/person closely associated
a)	Name                                     Advertisement	Jörg Brinkmann
2. Advertisement	Reason for the notification
a)	Advertisement                                     Position/status	CEO                                       Advertisement
b)	Initial notification/Amendment	Advertisement                                     Initial notification
3.	Advertisement Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name                                     Advertisement	H+H International A/S
b)	Advertisement                                     LEI	LEI:  3800GJODT6FV8QM841
Advertisement 4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)                                     Advertisement	Description of the financial instrument, type of instrument                                                                                                                 Identification code                                                                           Advertisement	Shares                                                                           DK0015202451
Advertisement                                     b)	Nature of the transaction	Purchase Advertisement
c)	Price(s) and volume(s)                                     Advertisement	Price(s)	Volume(s)
		DKK 110 per share	2,000
Advertisement                                     d)	Aggregated information                                     –  Aggregated volume                                     –  Aggregated price Advertisement	Aggregated information                                     2000 shares                                     DKK 220,000
Advertisement                                     e)	Date of the transaction(s)	2025-03-10 Advertisement
f)	Place of transaction(s)                                     Advertisement	Copenhagen (XCSE)

Advertisement 1.	Details of the person discharging managerial responsibilities/person closely associated
a)                                     Advertisement	Name	Jörg Brinkmann                                     Advertisement
2.	Reason for the notification
Advertisement                                     a)	Position/status	Advertisement                                     CEO
b)	Advertisement                                     Initial notification/Amendment	Initial notification
Advertisement 3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)                                     Advertisement	Name	H+H International A/S
Advertisement                                     b)	LEI	LEI:  3800GJODT6FV8QM841 Advertisement
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                     Advertisement
a)	Description of the financial instrument, type of instrument                                                                                                                 Advertisement Identification code	Shares                                                                           Advertisement DK0015202451
b)	Nature of the transaction Advertisement	Purchase
c)                                     Advertisement	Price(s) and volume(s)	Price(s)	Volume(s) Advertisement
		DKK 107.6 per share	2,000
d)	Advertisement Aggregated information                                     –  Aggregated volume                                     –  Aggregated price	Aggregated information                                     Advertisement 2000 shares                                     DKK 215,200
e)	Advertisement                                     Date of the transaction(s)	2025-03-11
Advertisement f)	Place of transaction(s)	Copenhagen (XCSE)                                     Advertisement

CONTACT:

For further information please contact:
Niclas Bo Kristensen
Head of Investor Relations & Treasury
+45 24 48 03 67
Nbk@hplush.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h-h-international-a-s/r/transactions-for-persons-discharging-managerial-responsibilities,c4118773

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/transactions-for-persons-discharging-managerial-responsibilities-302401339.html

Advertisement

WASHINGTON, March 13, 2025 /PRNewswire/ — “CBC Summit is excited to announce the expansion of its highly successful US-based event to London on March 17, 2026.“

Introduced in 2023, CBC Summit USA has become a must-attend annual gathering in Washington, D.C., for crypto banking, compliance, and payments executives; featuring participation from industry leaders such as Coinbase, Kraken, Ledger, Binance, Elliptic, Stripe, Robinhood, Anchorage Digital Bank, Silicon Valley Bank, Ibanera, and BCB Group.

CBC Summit Europe marks a significant step in expanding the event’s global reach, offering professionals across Europe the opportunity to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.

CBC Summit Europe will provide a platform for over 100 European industry leaders, executives, and government agencies to engage in high-level discussions on the latest trends, challenges, and solutions shaping the global crypto banking ecosystem.

CBC Summit Europe topics will include:

• The current state of fintech and crypto banking in the UK and Europe – insights into the struggles and solutions to onboarding with crypto friendly banks for fiat on-ramp and off-ramp services in the UK and Europe.
• Building the new Financial Infrastructure – exchanges and partners are building out their own Layer 2 networks to ease transition to DeFi and map out a new financial infrastructure. What comes next?
• Navigating AML Challenges in the FCA & MiCA Era – adapting to evolving anti-money laundering regulations.
• Transforming Global Finance with Stablecoins & Cross-Border Payments – exploring their role in transforming global finance.
• Financial Crime Trends in Crypto & Fintech – What methods are criminals currently employing, and how is financial crime evolving in crypto?

“The expansion of CBC Summit USA to Europe reflects the growing importance of global collaboration in crypto banking, compliance, and payments” said Joshua Radbod, CEO of CBC Summit. “As the industry continues to evolve, bringing together global leaders from different regulatory environments is crucial for shaping its future.”

Registration & More Information: Registration is now open, and attendees are encouraged to secure their spots in advance. For more details on speakers, sessions, and sponsorship opportunities, visit https://www.cbcsummit.io/europe

About CBC Team: The CBC Team specializes in creating and operating events that address banking, compliance, and payments challenges in emerging industries. For more information, visit CBC Summit.

Media Contact: info@cbcsummit.io

View original content:https://www.prnewswire.co.uk/news-releases/cbc-summit-expands-to-europe-bringing-crypto-banking-compliance-and-payments-leaders-together-in-london-on-march-17-2026-302400124.html

Advertisement